Mithun Vinod Shah
Overview
Explore the profile of Mithun Vinod Shah including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
56
Citations
676
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Baranwal A, Langer K, Gannamani V, Rud D, Cibich A, Saygin C, et al.
Blood Adv
. 2025 Mar;
PMID: 40085959
Allogeneic stem cell transplant (alloHCT) is considered for all patients with myeloid neoplasms (MN) harboring TP53-mutations (TP53mut). The aim of this international study across 7 transplant centers in USA and...
2.
Shah M, Hung MBBS FRACP FRCPA K, Baranwal A, Kutyna M, Al-Kali A, Toop C, et al.
Blood Adv
. 2025 Mar;
PMID: 40085954
This retrospective analysis aimed to provide evidence-based risk-stratification of TP53-mutated (TP53mut) myeloid neoplasms (MN). Of 580 MN harboring TP53mut with variant allele frequency (VAF) ≥2%, 219 (37.8%), 194 (33.4%), 92...
3.
Shah M, Arber D, Hiwase D
Am J Hematol
. 2025 Mar;
PMID: 40066944
Alterations in the tumor suppressor gene TP53 are common in human cancers and are associated with an aggressive nature. Approximately 8%-12% of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML)...
4.
Badar T, Knutson K, Knutson K, Foran J, Foran J, Gangat N, et al.
Blood Adv
. 2024 Nov;
9(2):239-243.
PMID: 39571168
No abstract available.
5.
Shahzad M, Amin M, Daver N, Shah M, Hiwase D, Arber D, et al.
Blood Cancer J
. 2024 Nov;
14(1):202.
PMID: 39562552
TP53 is a tumor suppressor gene frequently mutated in human cancers and is generally associated with poor outcomes. TP53 mutations are found in approximately 5% to 10% of patients with...
6.
Singhal D, Kutyna M, Hahn C, Shah M, Hiwase D
Blood Cancer Discov
. 2024 Oct;
5(6):400-416.
PMID: 39422544
Therapy-related myeloid neoplasm (t-MN), characterized by its association with prior exposure to cytotoxic therapy, remains poorly understood and is a major impediment to long-term survival even in the era of...
7.
Wang E, Issa G, Erba H, Altman J, Montesinos P, DeBotton S, et al.
Lancet Oncol
. 2024 Oct;
25(10):1310-1324.
PMID: 39362248
Background: Ziftomenib (KO-539) is an oral selective menin inhibitor with known preclinical activity in menin-dependent acute myeloid leukaemia models. The primary objective of this study was to determine the recommended...
8.
Katamesh B, Nanaa A, He R, Viswanatha D, Greipp P, Bessonen K, et al.
Ann Hematol
. 2024 Aug;
103(10):4333-4336.
PMID: 39196377
No abstract available.
9.
Guilatco A, Shah M, Weivoda M
J Bone Oncol
. 2024 Jul;
47:100620.
PMID: 39072049
Therapy-related myeloid neoplasms (t-MN) are a growing concern due to the continued use of cytotoxic therapies to treat malignancies. Cytotoxic therapies have been shown to drive therapy-induced senescence in normal...
10.
Li M, Baranwal A, Gurney M, Shah S, Al-Kali A, Alkhateeb H, et al.
Blood Adv
. 2024 Apr;
8(12):3130-3139.
PMID: 38564774
Clonal cytopenia of undetermined significance (CCUS) is defined by a myeloid driver mutation in the context of otherwise unexplained cytopenia. CCUS has an inherent risk of progressing to myeloid neoplasm....